user avatar
David Russler-Germain, MD/PhD
@dgermain21
Oncology Instructor @SitemanCenter @WUSTLmed | lymphoma/leukemia researcher @LabFehniger | all views 100% my own
St. Louis, MO
Joined January 2009
897
Following
3,803
Followers
Posts
  • Pinned
    user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Jul 3, 2023
    Pretty much everyone who knows me knows I'm a big fan of bispecific antibodies for B-NHL. For a summary of key landmarks in this space, emerging evidence and lessons from recent clinical trials, and exciting new directions, check out our review:
    Frontiers | T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and...
    From frontiersin.org
    23K
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Feb 1, 2022
    Literally the last paragraph of the article reads:
    user avatar
    The New York Times
    @nytimes
    Feb 1, 2022
    Breaking News: Pfizer and its partner BioNTech are expected to ask the FDA as soon as Tuesday to authorize its Covid vaccine for children 6 months to 4 years old as a two-dose regimen. nyti.ms/3oALCR9
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Jun 21, 2022
    How do I teach the essentials of DLBCL to my co-fellows? See this folder for my slide-deck and PDFs of the references. Enjoy! wustl.box.com/s/k076bndfpjh0…
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Jan 20, 2023
    I'm prepping a talk and for the first time it dawned on me: why don't I put a QR code at the end that links to a Box drive folder of the PDFs of every reference I cited in the talk? Cool or dumb idea? Seems super obvious now...
    51K
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Apr 21, 2021
    If I had to give future heme/onc fellows one piece of advice not directly related to patient care, it'd be to read at 1+ paper every (week)day. Set aside 30 min to read something from NEJM, Lancet, JAMA, Blood, JCO, or any sub-journal. Save and highlight PDFs digitally.
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Jun 8, 2022
    So was I last person on earth to learn that NCI-designated cancer centers don’t have to accept Medicaid? Heard from few fellows at ASCO from other institutions (some of which I thought were safety-nets) that their cancer centers won’t treat patients on Medicaid. Help me process…
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Apr 27, 2022
    I’m honored to receive a 2022 LRF Postdoctoral Fellowship to support my work in @LabFehniger on lymphoma mouse models of FL/DLBCL. Many thanks to everyone supporting my physician-scientist training: Todd, Tim Ley, @nancybartlettMD, @KahlBrad, @DiPersioLab, and many others!
    user avatar
    Lymphoma Research Foundation
    @lymphoma
    Apr 27, 2022
    We are pleased to announce the 2022 LRF grantee class, with $5.7 million in grants awarded to early career and established scientists working on innovative lymphoma research. Read more about our grantees by visiting us at lymphoma.org/news/2022grant….
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Sep 16, 2023
    CART cells are revolutionizing B-NHL treatment. But… Let’s not sweep under the rug: (1) ~$400k product, ~$1M “total package” (2) ~1/4 patients required ICU care (3) Non-relapse mortality ~10% We need to acknowledge the downsides to make CART cells cheaper, faster, and safer.
    user avatar
    Eddie Cliff
    @Eddie_Cliff
    Sep 15, 2023
    The ALYCANTE trial of axi-cel in transplant ineligible DLBCL patients just out in @NatureMedicine 88.7% patients over the age of 65 Median PFS 11.8 months Grade 3/4 CRS 8.1% Grade 3/4 ICANS/neuro events 14.5% #lymsm
    43K
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Nov 6, 2022
    I’ve been asked to re-share some of my lymphoma teaching resources from @WUHemeOncFellow. So glad people find them useful! Focused review of RT for DLBCL: wustl.box.com/s/u04583yxw92e… Broad review of DLBCL for first year fellows: wustl.box.com/s/ekrn9y9rka1c…
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Jun 22, 2021
    Recently saw a patient for “new MDS” with Celiac dz, a prior small bowel resection, and was taking two zinc-containing supplements. Negative sequencing and FISH. Copper level below limit of detection, zinc level 3x ULN. IV cupric chloride to the rescue! Normal CBC now!
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Sep 30, 2022
    The @nytimes does a great job covering legitimate amazingness of CAR-T cell therapy for cancer. But they should follow-up those pieces with a series on how poorly insurance companies are behaving as they delay patients' access to this treatment for months without justification.
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Nov 5, 2023
    Replying to @VPrasadMDMPH
    Be the doctor you want taking care of your family members. Hard for that advice to lead you astray.
    4.1K
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Jan 5, 2021
    Sometimes I read prominent papers and I think, "What in the world is going on here? Why am I so confused?" Recently, I'm realizing it's because it's easy for authors to obfuscate the data and make plots of p-values instead of actual data. I'm staring at bar charts...of p-values.
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Oct 12, 2023
    After the polatuzumab ODAC, @Eddie_Cliff and I were very intrigued by the POLARIX subgroup analyses. This led to multiple discussions, and together with @nancybartlettMD, we've published our impressions of the polatuzumab COO interaction: ashpublications.org/blood/article/… #lymsm
    15K